Morphosys (MOR) has released an update.
MorphoSys AG has reported a first-quarter revenue of €27.5 million, mainly from royalties, with R&D expenses increasing to €85.2 million due to investments in drug development. The company has sold its tafasitamab rights to Incyte and is undergoing a takeover by Novartis, with shareholders offered €68 per share—a significant premium. Future financial forecasts have been withdrawn due to these major changes.
For further insights into MOR stock, check out TipRanks’ Stock Analysis page.
